Ten numbers in the abstract
Where each one falls
Where it lands on the map
the abstract, start to end
… 15% reduction in risk of lung cancer (OR 0.85, 95% CI 0.77 to 0.92), but this finding was not supported by sub-analysis of smoking-adjusted studies (OR 0.84, 95% CI 0.61 to 1.06).
… lung cancer risk, respectively (OR 1.10, 95% CI 0.93 to 1.26), (OR 0.86, 95% CI 0.70 to 1.02).
… cancer risk was related to insulin (OR 1.23, 95% CI 1.10 to 1.35).
… did not change for metformin (OR 0.81, 95% CI 0.67 to 0.95), …
… for other glucose-lowering drugs was 0.87 (95% CI 0.81 to 0.94).
… for other glucose-lowering drugs was 1.22 (95% CI 1.17 to 1.27).
… risk in patients with diabetes (OR 1.10, 95% CI 0.93 to 1.26; P = 0.000 …
… still increased lung cancer risk (OR 1.30, 95% CI 1.09 to 1.51).
← favours treatmentfavours comparator →
could be chanceAdverse events & safety
OR 0.850.77–0.92
Adverse events & safety
OR 0.840.61–1.06
Adverse events & safety
OR 1.100.93–1.26
Adverse events & safety
OR 0.860.70–1.02
Glycemic control
OR 1.231.10–1.35
Glycemic control
OR 0.810.67–0.95
Glycemic control
−0.87−0.94 to −0.81
Glycemic control
−1.22−1.27 to −1.17
Adverse events & safety
OR 1.100.93–1.26
Glycemic control
OR 1.301.09–1.51
MetforminSulfonylureas & glinidesInsulinOther glucose-loweringGlycemic controlAdverse events & safetyPharmacokinetics & dosing
1 / 3